NCT02595983 - The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

February 6, 2017

Study Completion Date

February 6, 2017

Conditions

Transthyretin (TTR)-Mediated AmyloidosisFamilial Amyloidotic Polyneuropathy (FAP)ATTR AmyloidosisFamilial Amyloid Neuropathies

Interventions

DRUG

Revusiran

500mg Revusiran by subcutaneous (sc) injection

Trial Locations (6)

Clinical Trial SIte, Paris

Clinical Trial SIte, Münster

Clinical Trial SIte, Porto

Clinical Trial SIte, Majorca

Clinical Trial Site, Umeå

Clinical Trial SIte, London